Skip to main content

Table 1 Baseline and hospitalization characteristics

From: MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy

Patients characteristics

N = 316

Age, median (IQR)

59 (53-65)

Gender (male; %)

191 (60.4%)

Race (%)

 

• Caucasian

107 (33.9%)

• African American

42 (13.3%)

• Asian

15 (4.7%)

• Hispanic

91 (28.8%)

• Unknown

61 (19.3%)

Baseline liver disease (%)

 

• Hepatitis B

10 (3.2%)

• Hepatitis C

110 (35%)

• Alcohol

98 (31%)

• Non-alcoholic fatty liver disease

31 (10%)

• Autoimmune hepatitis

10 (3%)

• Primary biliary cirrhosis/Primary sclerosing cholangitis

10 (3%)

• Hemochromatosis

6 (2%)

• Post-liver complication

9 (3%)

• Cryptogenic/unspecified

58 (19%)

Presence of TIPS (%)

15 (4.7%)

Prior history of HE (%)

161/289 (55.7%)

MELD, median (IQR)

22 (17-28)

Primary reason of admission

 

• HE

198 (62.7%)

• Liver related-complication

88 (27.8%)

• Non-liver related

30 (9.5%)

Acute hepatitis (%)

32 (10.1%)

Treatment

 

• Lactulose alone

61 (19.3%)

• Lactulose + rifaximin

240 (75.9%)

• Rifaximin alone

10 (3.2%)

• Othera

5 (1.6%)

Use of antibiotics other than rifaximin during the admission (%)

181 (57.3%)

Length of stay, days, median (IQR)

8 (3.25-14.75)

  1. aMetronidazole, neomycin, supportive